MTOR and gastric adenocarcinoma: A high number of mutations in the PI3K-AKT-mTOR pathway (NMP) genes may predict primary resistance to ICIs in dMMR/MSI-H gastric adenocarcinoma, and the use of PI3K-AKT-mTOR inhibitors as adjuncts to immunotherapy is recommended for patients with high NMP mutations [104].